Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that ...

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

A new review of nearly 100,000 participants suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), popular ...

Amid soaring global demand for glucagon-like peptide-1 (GLP-1) medications and widespread concerns about affordability and access, the World Health Organization (WHO) released its global comprehensive ...

Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

GLP-1 receptor agonists are associated with a lower risk of dementia than DPP-4 inhibitors in dialysis patients with diabetes.

A new study finds a possible association between GLP-1 drugs like semaglutide and chronic cough, though the authors are ...

Just this week, the World Health Organization released new guidelines recommending GLP-1 therapies as a long-term treatment for adults with obesity.